Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC

Share :
Published: 4 Jun 2023
Views: 202
Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA

Dr Wakelee talks to ecancer at ASCO 2023 about data she presented from the study KEYNOTE-671.

In patients with non-small cell lung cancer (NSCLC), pembrolizumab has previously shown efficacy as a monotherapy in the adjuvant and advanced settings and in combination with chemotherapy in metastatic disease.

KEYNOTE-671 evaluated the addition of pembrolizumab to platinum-based chemo as neoadjuvant therapy followed by resection and pembrolizumab vs placebo as adjuvant therapy in patients with early stage NSCLC.

Pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab provided a statistically significant and clinically meaningful improvement in EFS, pCR and mPR in patients with resectable stage II, IIIA, and IIIB NSCLC.

We presented the results of IND.227, a randomised phase III clinical trial evaluating the addition of pembrolizumab to standard pemetrexed and cisplatin chemotherapy for patients with inoperable pleural mesothelioma in the advanced or metastatic setting. 

The trial enrolled 440 patients with inoperable pleural mesothelioma. The trial was led by the Canadian Cancer Trials Group in collaboration with our colleagues from the National Cancer Institute of Naples in Italy and the French Cooperative Thoracic Intergroup in France. The CCTG has previously published a small phase II clinical trial which was published earlier this year in a separate group of patients in The Journal of Thoracic Oncology which reported promising results. 

This phase III clinical trial enrolled patients who were 18 years or older, had performance status of 0 or 1 and met other standard eligibility criteria. Patients had to have inoperable disease, they may have had adjuvant or neoadjuvant chemotherapy but systemic therapy for advanced disease was not permitted. The trial demonstrated that the addition of pembrolizumab to pemetrexed and platinum chemotherapy significantly prolonged overall survival by reducing the risk of death by 21% with a hazard ratio of 0.79. Further, there was an improvement in the two-year overall survival from 33% on the chemotherapy arm to 39% on the pembrolizumab arm. There was also improvement in the three-year overall survival, improving from 17% on the chemotherapy arm to 25% on the pembrolizumab arm. This was despite the fact that more patients on the chemotherapy arm subsequently proceeded to have immune checkpoint inhibitors as a second-line of therapy, predominantly with nivolumab and ipilimumab which is known to have activity in this setting.

Progression free survival was also significantly longer for the pembrolizumab arm with a hazard ratio of 0.80 with a 20% reduction in the risk of progression or death with a p-value of 0.037. The objective response rate was also higher on the pembrolizumab arm with a response rate of 62% compared to just 38% on the chemotherapy arm. While the primary endpoint was overall survival, tumour shrinkage is also an important endpoint for patients, particularly for those that would be at risk for early progressive disease.

The addition of pembrolizumab to pemetrexed and cisplatin was tolerable with a manageable side effect profile. So, in summary, the addition of pembrolizumab to pemetrexed and platinum improved overall survival with a 21% reduction of risk, improved progression free survival with a 20% reduction in risk and increased overall response rate and therefore should be considered a new option for this patient population.

Chemotherapy has been the standard treatment option for patients with inoperable pleural mesothelioma for over two decades until recently when another trial evaluating nivolumab and ipilimumab demonstrated an improvement in overall survival with the immune checkpoint inhibitor combination, similar to the results on the IND.227 clinical trial. However, in the IND.227 clinical trial there was also a higher response rate, more patients on the IND.227 chemotherapy arm subsequently received immune checkpoint inhibitors and, although it was not directly compared, has a more tolerable safety profile. 

Although mesothelioma is a devastating cancer and international collaborations are needed to be able to conduct phase III clinical trials to evaluate new treatment strategies, the CCTG and its collaborators and other groups are already planning new clinical trials to evaluate new treatment options which may improve the outcome from this disease. In addition, we await the results of two other randomised phase III trials evaluating immune checkpoint inhibitors compared with chemotherapy.